![\"Man](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/03\/happy-investor-16_9-1200x675.jpg\")
<\/p>\nASX healthcare stocks are a popular option for investors seeking defensive assets with long-term structural growth.<\/p>\n
These shares can offer portfolio diversification, drive high margins, and some of them have huge potential upside. <\/p>\n
Here are three ASX healthcare stocks on my radar this week, and analysts are tipping upside well over 100% over the next 12 months.<\/p>\n
<\/p>\n
Image source: Getty Images<\/p>\n
Pro Medicus Ltd (ASX: PME<\/a>) <\/p>\n The beaten-down medical imaging technology stock has dropped another 1.7% in Wednesday afternoon trade, to $125.69 a piece. The decline is part of a long string of declines off the back of sector-wide headwinds, which have seen the share price crash 62% from an all-time high recorded in mid-2025. <\/p>\n Sentiment didn’t improve when the company posted a record-breaking half-year FY26<\/a> result in mid-February. Its revenue was up 28%, and profit jumped nearly 30%, but it still missed investors’ high expectations.<\/p>\n But Pro Medicus has won several contracts so far in 2026, including two $40 million<\/a> five-year contract renewals with its wholly owned US subsidiary, Visage Imaging, earlier this month. <\/p>\n I think the stock is trading well below value right now. And analysts<\/a> are tipping potential for a 139% upside to $300 per share over the next 12 months.<\/p>\n Telix Pharmaceuticals Ltd (ASX: TLX<\/a>) <\/p>\n Telix shares are racing higher on Wednesday<\/a>, recovering some losses seen during a sharp sell-off last year.<\/p>\n Despite several recent headwinds, it looks like Telix shares are finally rebounding. The positive sentiment started when it filed a key regulatory approval in Europe. News of positive results from its Global Phase 3<\/a> ProstACT study last week, followed by an announcement that the company has resubmitted<\/a> its New Drug Application (NDA) to the US FDA for its brain cancer imaging candidate TLX101-Px (Pixclara\u00ae), has seen investors flock to the stock.<\/p>\n Analysts<\/a> tip the ASX healthcare stock to jump 156% to $31.59 a piece over the next 12 months.<\/p>\n Clarity Pharmaceuticals Ltd (ASX: CU6<\/a>) <\/p>\n The clinical-stage radiopharmaceutical company’s shares jumped higher this week on the back of good\u00a0news<\/a>\u00a0about the development of new trial data for its prostate cancer imaging technology. The findings will be used as a basis to form a new drug submission to the FDA.<\/p>\n It’s good news after Clarity shares suffered from volatility over the past five months, fluctuating anywhere between $5.70 and $2.73.\u00a0<\/p>\n